UBE2M

Across TCGA pan-cancer cohorts, UBE2M mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated UBE2M data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher UBE2M mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2M expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where UBE2M mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.580	0.885	.006	31	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
HNSC	DFS	Tertile	III,IV	0.489	0.744	.014	6	view →
PDAC	OS	Quartile	All	0.278	0.548	.019	5	view →
LUAD	DFS	Median	II,III,IV	0.990	0.684	.006	4	view →
GBM	OS	Tertile	All	0.955	0.777	.015	3	view →
LSCC	OS	Median	III,IV	0.784	0.917	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

UBE2M–CCRCC (DFS)

Open the CCRCC breakdown →